Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Robert Byrne: Absorb, Synergy, And The Future Of Coronary Stents

Executive Summary

One of the most controversial, and potentially impactful, questions in medical device development today is how to better prevent late events, especially late stent-thrombosis, in coronary stent patients. The two leading answers to this question are a completely bioresorbable drug-eluting stent and a metal drug-eluting stent with a bioresorbable polymer, but there may be even more ideas on the horizon. One of the leading experts in the field and a cardiologist with experience with most of these new technologies, Robert Byrne of Deutsches Herzzentrum in Munich, recently talked to Medtech Insight about the questions that still need to be answered in this field and how it can move forward.

Advertisement

Related Content

Abbott's Absorb GT1 Is First FDA-Approved Absorbable Coronary Stent
EuroPCR Stent Wrap-Up: Biotronik’s Magmaris magnesium stent, Reva’s Fantom Polymer DES, and Elixir’s DESolve
CLINICAL CORNER: Medtronic’s Prestige LP Cervical Disc; Biotronik’s Orsiro DES, More
Market Update: Growth And Opportunities In Peripheral Artery Disease
INTERVIEW: Bioabsorbable Stents? No, Drug-Filled Stents Is Way Forward, Says Medtronic Cardiac Intervention CMO
Absorbing Debate: Boston Scientific, Abbott Differ On Whether The Future Of Stents Is To Disappear
TCT 2015: Abbott's Absorb On Par With Metal DES But Longer Data Still Needed
Medtronic Starts Next-Gen Drug-Eluting Stent Trials
Stents Vs. Balloons Question For Peripheral Artery Disease Gets Attention At Veith
EuroPCR 2011: DESs with absorbable polymers shown to beat those with durable polymers for the first time

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

MT103843

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel